Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
03/2003
03/06/2003WO2003000240A3 Stable powder inhalation dosage formulation
03/06/2003WO2003000190A3 Liposomal encapsulation of glycosaminoglycans for the treatment of arthritic joints
03/06/2003WO2002096367A3 Targeted multivalent macromolecules
03/06/2003WO2002094218A3 Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
03/06/2003WO2002085447A3 Microprojection array having a beneficial agent containing coating
03/06/2003WO2002074200B1 Formulations containing propofol and a sulfoalkyl ether cyclodextrin
03/06/2003WO2002066511A3 Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders
03/06/2003WO2002060929A3 Polymer conjugates of neublastin and methods of using same
03/06/2003WO2002060501A3 Hydrogel wound dressing,preparation and use thereof
03/06/2003WO2002056867A3 Extended release pharmaceutical compositions containing beta-lactam antibiotics
03/06/2003WO2002055106A3 Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
03/06/2003WO2002051994A8 Polypeptides
03/06/2003WO2002051383A3 Controlled release of anti-arrhythmic agents from a biodegradable polyethylene oxide hydrogel for local application to the heart
03/06/2003WO2002043661B1 Recombinant anti-cd30 antibodies and uses thereof
03/06/2003WO2002041837A3 Treatment of mucositis
03/06/2003WO2002028376A3 Chrono delivery formulations and method of use thereof
03/06/2003WO2002022132A8 Novel topical oestroprogestational compositions with systemic effect
03/06/2003WO2001089483A9 Tablets and methods for modified release of hydrophilic and other active agents
03/06/2003US20030045865 Compositions and techniques for localized therapy
03/06/2003US20030045705 Backbone modified oligonucleotide analogues
03/06/2003US20030045690 Having a mean diameter of 200-2000 nm, obtained by solidification from a mixture comprising fibrinogen, thrombin and Factor XIII in an water in oil emulsion
03/06/2003US20030045681 Antibody for use in the treatment of angiogenesis
03/06/2003US20030045587 For solubilizing in a polar solvent an insoluble drug such as dantrolene or dilantin, comprising a sugar and/or C2-C3 di- or higher alcohol, and a second polar organic compound having an amide and/or an ammonium group, e.g. acetamide
03/06/2003US20030045583 Novel succinate salt of O-desmethyl-venlafaxine
03/06/2003US20030045580 Making, by coating ibuprofen or its salt with hydroxypropylmethylcellulose, methylcellulose, sodium carboxymethylcellulose, hydroxypropylcellulose or gelatin as binder, in specified weight percents; dosage forms
03/06/2003US20030045579 Compounds and compositions for delivering active agents
03/06/2003US20030045576 Composition for pain mediation and apparatus and method of use thereof
03/06/2003US20030045563 Comprises cyclooxygenase-2 inhibitors (celecoxib, rofecoxib); water solubility; vasodilation/headache relief; for inhibition of precipitation and/or crystallization in gastrointestinal fluids
03/06/2003US20030045544 Bactericides for the oral region of animals using 3-carboxy-4-oxo quinoline or 1,8-naphthyridine derivatives or 1-cyclopropyl-3-carboyx-4-oxo quinolizine derivatives
03/06/2003US20030045543 Systems and methods for treating a mucosal surface
03/06/2003US20030045522 Novel galenical form for oral administration with prolonged release of molsidomine
03/06/2003US20030045513 Solution comprising: a) water; b) propylene glycol; c) 2-propanol; and d) hydrocortisone; dispensing solution into an external ear canal and contacting a wick with the solution to expand the wick within the canal
03/06/2003US20030045505 Oligosaccharide having at least a D-galactose unit bound by an alpha (1-6) bond with a sucrose unit; second component is a molecule positively charged at physiological pH and that promotes pinocytosis or membrane penetration
03/06/2003US20030045503 Topical formulation comprising glucosamine and chondroitin in an anhydrous base that is stable for at least 10 days.
03/06/2003US20030045502 Oral intake solution
03/06/2003US20030045481 Use of specific amino acids reduces or prevents coloration attributable to a saccharide stabilizer; especially useful in pharmacologically active proteinaceous compositions
03/06/2003US20030045476 Heart homing conjugates
03/06/2003US20030045465 RTransport polymer comprising a linear or branched peptide having 10-300 amino acid residues, having from about 5 to 100% histidine residues; drug delivery, especially gene therapy and cancer chemotherapy
03/06/2003US20030045461 Composition and methods of esterified nitroxides gated with carboxylic acids
03/06/2003US20030045456 Complex comprising OCIF and polysaccharide
03/06/2003US20030045454 Sustained release formulation
03/06/2003US20030044961 Compositions for transferring active compounds in a cell-specific manner
03/06/2003US20030044915 Method for preparing a polypeptide soluble in an aqueous solvent in the absence of detergent
03/06/2003US20030044845 Novel therapeutic agents for membrane transporters
03/06/2003US20030044528 Spraying a solution wherein a poorly soluble drug is dissolved in a plasticizer, and an aqueous solution and/or water dispersion of a water-soluble polymer, from nozzle outlets simultaneously and separately.
03/06/2003US20030044479 Process for the production of pure guar meal
03/06/2003US20030044474 High molecular weight, lipophilic, orally ingestible bioactive agents in formulations having improved bioavailability
03/06/2003US20030044469 Retinol or retinoic acid encapsulated in a chitosan matrix, particularly in combination with carboxymethyl cellulose, to form microcapsules with improved stability of the retinol
03/06/2003US20030044467 Gel composition and methods
03/06/2003US20030044466 Oral drug delivery systems where drug is administered with any of specified substances that induce "fed mode" in stomach such as tryptophan dipeptide or cetylpyridinium chloride to prolong retention in stomach; bioavailability
03/06/2003US20030044464 Sustained-release, oral pharamaceutical forms of formulation
03/06/2003US20030044463 Sustained release of microcrystalline peptide suspensions
03/06/2003US20030044456 A hydrolysate gelatin is extracted from poultry skins, bones and/or tendons, with an isoelectric point at pH 7-10, treated with acid solution, then hydrolysis; use for food, medicine and cosmetics
03/06/2003US20030044453 An application to the skin and/or mucosa consisting of active substance solid dispersions in a matrix; reduce skin irritation, efficient drug delivery, improve penetration of hydrophilic medicinal substances through the skin
03/06/2003US20030044450 Oral vaccines
03/06/2003US20030044446 A multilayered film comprising a first, water-soluble adhesive layer to be placed in contact with a mucosal surface and a second, water-erodible non-adhesive backing layer that controls residence time; drug delivery from mouth
03/06/2003US20030044436 Prepared by melt processing a hydrophobic polymer composition that includes repeating pyrrolidone/alkylene groups containing at least 10 carbon atoms, and a hydrophilic polymer composition including repeating carboxylic or hydroxyl groups
03/06/2003US20030044415 Method for producing or enhancing a T-cell response against a target cell using a complex comprising an HLA class I molecule and an attaching means
03/06/2003US20030044408 Surface modification for improving biocompatibility
03/06/2003US20030044405 Sustained release; drug delivery; tissue adhesive
03/06/2003US20030044402 Oligo(ethylene glycol)-terminated 1,2-dithiolanes and their conjugates useful for preparing self-assembled monolayers
03/06/2003US20030044383 Tissue specific adenoviral vectors
03/06/2003US20030044374 Topical composition, topical composition precursor, and methods for manufacturing and using
03/06/2003US20030044356 Composition for nasal solution sprays having effective component of 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one)
03/06/2003US20030042638 Method of solubilizing and encapsulating itraconazole
03/06/2003US20030041780 Water dispersible compositions containing natural hydrophilic water-insoluble pigments, methods of preparing same and their use
03/06/2003DE20219662U1 Orally administered sponge-like material, useful as satiation agent or drug carrier, is pretreated by oxidation in aqueous solution to reduce strength and prevent gastrointestinal blockage
03/06/2003DE10129369C1 Wasserlösliches, einen Aminozucker aufweisendes Antibiotikum in Form eines Pol ysaccharid-Konjugats Water-soluble, an amino sugar exhibiting antibiotic in the form of a pole ysaccharid conjugate
03/06/2003CA2485193A1 Stable coated microcapsules
03/06/2003CA2465676A1 Compositions and techniques for localized therapy of restenosis
03/06/2003CA2459974A1 Emu-based formulations for wound treatment related application information
03/06/2003CA2458866A1 Compositions and methods of treating diabetes
03/06/2003CA2458854A1 Helicobacter pylori vaccination
03/06/2003CA2458448A1 Spontaneous emulsions containing cyclosporine
03/06/2003CA2458443A1 Bioadhesive compositions and methods for enhanced mucosal drug absorption
03/06/2003CA2458394A1 Lipophilic drug compositions
03/06/2003CA2457979A1 A delivery system
03/06/2003CA2457885A1 Antimicrobial and anti-inflammatory peptides
03/06/2003CA2457590A1 Method and apparatus for acne treatment
03/06/2003CA2457341A1 A new extended release oral dosage form
03/06/2003CA2457339A1 A new extended release oral dosage form
03/06/2003CA2457196A1 Compositions containing itraconazole and their preparation methods
03/05/2003EP1288304A2 Self-assembled, defective, non-self-propagating viral particles
03/05/2003EP1288264A1 Gelling composition
03/05/2003EP1288228A1 BMP-2-derived peptides having osteogenetic activity and osteogenetic accelerator containing the same
03/05/2003EP1287830A1 Use of methioninase as an antitumor agent in anti-methionine chemotherapy
03/05/2003EP1287823A1 Pharmaceutical excipient having improved compressibility
03/05/2003EP1287822A2 Mesalazine controlled release oral pharmaceutical compositions
03/05/2003EP1287821A1 Multiparticulate formulations of atorvastatin calcium having a modulated rate of drug release
03/05/2003EP1287820A1 Aerosol compositions
03/05/2003EP1287147A2 Immunotoxin fusion proteins and means for expression thereof
03/05/2003EP1287140A1 Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof
03/05/2003EP1287130A2 Mammalian cytokine receptor subunit proteins, related reagents and methods
03/05/2003EP1287039A1 Amphiphilic macrocyclic derivatives and their analogues
03/05/2003EP1286758A2 Emulsifiers
03/05/2003EP1286705A2 Bioconjugates of nanoparticles as radiopharmaceuticals
03/05/2003EP1286703A2 Methods and compounds for controlled release of recombinant parvovirus vectors
03/05/2003EP1286700A2 Tumor activated prodrug compounds
03/05/2003EP1286699A2 Composition for delivery of compounds to cells
03/05/2003EP1286665A2 Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases
1 ... 1162 1163 1164 1165 1166 1167 1168 1169 1170 1171 1172 1173 1174 1175 1176 1177 1178 1179 1180 1181 1182 ... 1712